The mean annual infection rate (n=18) was 2.00 in the first year and 1.44 in the second. Total number of infections in year one was 31 episodes with 22 respiratory infections, and in year two it was 25 episodes with 13 respiratory infections.
SCIg is an established therapy in many European countries. Australia is slowly transitioning long established IVIg patients to SCIg. Since 2014, the Department of Clinical Immunology and Allergy at Westmead Hospital has successfully trained and transitioned 50 patients from IVIg to SCIg. 80% of these patients have PID and the other have secondary immunodeficiency (SID) from immunosuppressive agents for underlying autoimmune disease. The majority of SCIg patients were Ig experienced.
This audit has three aims. The first aim is to evaluate the QOL of patients on SCIg, specifically focusing on the frequency of infections quantified by the number of days off work/school, the number of days on antibiotics, and general wellbeing. The second aim is to evaluate random Ig levels and evidence of end-organ damage. The third aim is to evaluate the healthcare cost savings of SCIg versus IVIg. QOL surveys of 30 randomly selected PID patients were conducted by phone.
Our audit found that 98% of patients are happy with their QOL on SCIg, with all reporting significantly decreased episodes of infection and antibiotic use, with minimal side effects. There was a 90% improvement in random IgG levels and measures of lung function testing. We also demonstrate a significant reduction in cost to NSW Health, with over $1000 saved per SCIg infusion compared to IVIg. Background: Patients with Primary immunodeficiency (PID) are susceptible to gastrointestinal symptoms, poor respiratory function and malnutrition. However, there is limited research assessing the prevalence of malnutrition and associated factors in this population. This study aimed to determine the prevalence of malnutrition amongst a PID cohort and associations with impaired bone mineral density (BMD), declining respiratory function (FEV1) and gastrointestinal symptoms.
Methods: A prospective, single centre, study was conducted in a tertiary hospital in Melbourne. A survey was sent to 110 patients diagnosed with PID examining presence of gastrointestinal symptoms and malnutrition. Malnutrition was defined as a Body Mass Index (BMI, kg/m 2 ) <18.5; or weight loss >5-10% over 12 months combined with BMI <20 if <70 years, or <22 if ≥70 years. Patient demographics, pre-existing gastrointestinal and respiratory disease, BMD and FEV1 (% predicted) results were collected from a database.
Results: 44 patients (40%) completed the survey. 48% were male (n = 21) with a mean (SD) age of 47 (17) . 50% of patients (n = 22) were diagnosed with Common Variable Immune Deficiency and the remaining had other PID. Impaired BMD was evident in 48% patients (n = 21). Patients with respiratory disease (n =30, 68%) had a significantly lower FEV1, mean difference -15.0 (95%CI -27.6 to -2.4, P = <0.05). There was a significant association between malnutrition (n = 12, 27%) and gastrointestinal disease (n = 10, 23%) (P = 0.015). Malnourished patients reported significantly more gastrointestinal symptoms, mean difference 1.5 (95%CI 0.1-2.8, P = 0.04). Patients with malnutrition were also more likely to have impaired BMD and lower FEV1 however this did not reach statistical significance.
Conclusion:
There is a high prevalence of malnutrition and impaired BMD amongst PID patients. Malnutrition was associated with pre-existing gastrointestinal disease and significantly more gastrointestinal symptoms. Subcutaneous Immunoglobulin (SCIg) has been treatment of choice for patient with Primary Immunodeficiency Disease (PID). Although, Australia is slowly converting suitable IVIg patients to SCIg, this has been the preference in many European Countries for many years and many success stories has been recorded, targeting patients' better quality of life since the switch from Intravenous Immunoglobulin (IVIg) (Chapel & Gardulf, 2013) .
P54 SUCCESS AND CHALLENGES WITH SCIG TRAINING AND
The department of Clinical Immunology at Westmead Hospital initiated a SCIg program in 2014 with over 50 PID patients successfully attending their treatment at home. The majority of the patients were transitioned from IVIg to SCIg and a few naive to Ig treatment. SCIg training is performed in a nurse led clinic with the trained registered nurses working very closely with the specialist Immunologist. The clinic treats patients from other departments such as Neurology, Rheumatology as well as Immunology and allergy. All staff working in the clinic are capable to treat and train SCIg patients. This poster will cover the challenges from a nurse's perspective that the clinic has encountered since the start of the program.
Challenges such as recruiting, patient training, patient compliance, adverse reaction, equipment (usage and ordering process), and also issues encountered with product ordering and pickup processes. Discussion will also highlight trouble shooting of these issues and recommendations will be made. The poster will also cover the success so far of involving and training the patients' general practitioner in cases where patients require some assistance. Chapel H and Gardulf A. (2013) . Subcutaneous immunoglobulin replacement therapy: the European experience. Curr Opin Allergy Clin Immunol. 13(6):623-9. doi: 10.1097/ACI.0000000000000013.
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